Opioid Receptor Agonists Pipeline Research Report 2022: Insights on 40+ Companies and 40+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Opioid Receptor Agonists – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.

This “Opioid Receptor Agonists – Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Opioid Receptor Agonists pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The companies and academics are working to assess challenges and seek opportunities that could influence Opioid Receptor Agonists R&D. The therapies under development are focused on novel approaches to treat/improve Opioid Receptor Agonists.

Opioid Receptor Agonists Emerging Drugs Chapters

This segment of the Opioid Receptor Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Opioid Receptor Agonists Emerging Drugs

LTX-03: Acura Pharmaceuticals

LTX-03 is being developed by Acura Pharmaceuticals. In June 2020, Acura Pharmaceuticals entered into License, Development and Commercialization Agreement, which was amended in October 2021, with Abuse Deterrent Pharmaceuticals, LLC, (“AD Pharma”) and a special purpose company representing a consortium of investors that will finance Acura’s operations through July 2021 and reimburse for development of LTX-03. AD Pharma has exclusive commercialization rights in the United States to LTX-03.

TRV-734: Trevena

Trevena is developing TRV734 for use in medication-assisted therapy for the treatment of opioid use disorder. It targets the mu receptor, but with an optimized mechanism of action that preferentially engages the signaling pathway responsible for therapeutic effect, with reduced activation of the signaling pathway responsible for mu receptor-mediated adverse effects.

Opioid Receptor Agonists: Therapeutic Assessment

This segment of the report provides insights about the different Opioid Receptor Agonists drugs segregated based on following parameters that define the scope of the report.

Major Players in Opioid Receptor Agonists

There are approx. 40+ key companies which are developing the therapies for Opioid Receptor Agonists. The companies which have their Opioid Receptor Agonists drug candidates in the most advanced stage, i.e. Phase II include, Acura Pharmaceuticals.

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Opioid Receptor Agonists drugs?
• How many Opioid Receptor Agonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Opioid Receptor Agonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Opioid Receptor Agonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Opioid Receptor Agonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Trevena
• Titan Pharmaceuticals
• Lumosa Therapeutics
• Astraea Therapeutics
• Alar Pharmaceuticals
• Ensysce Biosciences

Key Products

• TRV-734
• TP-2021
• TRV-250
• LT5001
• ALA-1000
• PF 614

Key Topics Covered:

Introduction

Executive Summary

Opioid Receptor Agonists: Overview

• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

• Comparative Analysis

Drug Name: Company Name

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

LTX 03: Acura Pharmaceuticals

• Product Description
• Research and Development
• Product Development Activities

Early stage products (Phase I)

• Comparative Analysis

TRV-734: Trevena

• Product Description
• Research and Development
• Product Development Activities

Preclinical stage products

• Comparative Analysis

Drug Name: Company Name

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

Opioid Receptor Agonists Key Companies

Opioid Receptor Agonists Key Products

Opioid Receptor Agonists- Unmet Needs

Opioid Receptor Agonists- Market Drivers and Barriers

Opioid Receptor Agonists- Future Perspectives and Conclusion

Opioid Receptor Agonists Analyst Views

Opioid Receptor Agonists Key Companies

Appendix

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/k19wi7

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900